| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.TIPS.2006.05.008 |
| P698 | PubMed publication ID | 16766048 |
| P50 | author | Stefan Offermanns | Q2337253 |
| P433 | issue | 7 | |
| P304 | page(s) | 384-390 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target | |
| P478 | volume | 27 |
| Q51592860 | A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: synthesis and in vitro evaluation. |
| Q37635019 | Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization |
| Q37536057 | Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A: WO2008051403. |
| Q35025103 | Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms |
| Q37720336 | BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activation |
| Q28583868 | Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists |
| Q39064720 | Constitutive expression of HCA(2) in human retina and primary human retinal pigment epithelial cells |
| Q37998115 | Diagnosis and treatment of severe hypertriglyceridemia |
| Q51744937 | Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor. |
| Q39735403 | Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia |
| Q37230403 | Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers |
| Q43159242 | Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. |
| Q35132366 | Effects of niacin on atherosclerosis and vascular function |
| Q46627734 | Effects of short-term niacin treatment on plasma lipoprotein concentrations in African green monkeys (Chlorocebus aethiops). |
| Q24316354 | Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells |
| Q46823789 | Elucidation of signaling and functional activities of an orphan GPCR, GPR81. |
| Q26764724 | Emerging preclinical pharmacological targets for Parkinson's disease |
| Q37097541 | Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. |
| Q36651652 | Familial dyslipidaemias: an overview of genetics, pathophysiology and management |
| Q42168337 | Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions. |
| Q34171831 | Future of GPR109A agonists in the treatment of dyslipidaemia |
| Q38025858 | G protein-coupled receptors for energy metabolites as new therapeutic targets |
| Q28287747 | GPR109A and vascular inflammation |
| Q40154290 | Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy |
| Q46476511 | Glucose intolerance induced by glucocorticoid excess is further impaired by co-administration with β-hydroxy-β-methylbutyrate in rats. |
| Q35575144 | High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice |
| Q37667487 | Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review |
| Q34565228 | Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages |
| Q36102106 | Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice |
| Q42203740 | Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid |
| Q38948892 | Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments. |
| Q30414585 | Naturally occurring HCA1 missense mutations result in loss of function: potential impact on lipid deposition |
| Q24297428 | Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A) |
| Q90193087 | Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A |
| Q35608570 | Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis |
| Q51545588 | Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells. |
| Q28575089 | Niacin stimulates adiponectin secretion through the GPR109A receptor |
| Q37376937 | Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia |
| Q42834982 | Nicotinic acid impairs assembly of leading edge in glioma cells |
| Q49965720 | Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling |
| Q37679063 | Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation |
| Q34624990 | Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells |
| Q34487985 | Nicotinic acid modulates intracellular calcium concentration and disassembles the cytoskeleton |
| Q34712851 | Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells |
| Q33927010 | Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation. |
| Q28298974 | Nicotinic acid receptor agonists differentially activate downstream effectors |
| Q39303280 | Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis |
| Q37529810 | Novel patent publications on high-affinity nicotinic acid receptor agonists |
| Q90679977 | Oligomeric Receptor Complexes and Their Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New Biological Principle for Integration of Signals in the CNS |
| Q37028758 | Orphan GPCR research |
| Q38351961 | Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). |
| Q46082621 | Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats |
| Q35575652 | Retinal transfer of nicotinate by H+ -monocarboxylate transporter at the inner blood-retinal barrier |
| Q39132612 | Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease |
| Q33789758 | Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3 |
| Q43423740 | Supplementing healthy rats with a high-niacin dose has no effect on muscle fiber distribution and muscle metabolic phenotype |
| Q35660100 | The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling |
| Q31051889 | The hypophagic response to heat stress is not mediated by GPR109A or peripheral β-OH butyrate |
| Q37621301 | The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. |
| Q41871296 | Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid |
| Q34361793 | Upregulation of GPR109A in Parkinson's disease |
| Q48379634 | β-Hydroxybutyric acid inhibits growth hormone-releasing hormone synthesis and secretion through the GPR109A/extracellular signal-regulated 1/2 signalling pathway in the hypothalamus |
Search more.